Vericel Corp (VCEL)

• Market cap: $1.87B
• 1 day: -3.35%
• 5 days: -1.43%
• 1 month: -10.79%
• 3 months: -14.93%
• 6 months: -31.85%
• Year to date: -35.06%
• 1 year: -28.33%
• 5 years: 113.04%
• 10 years: 1,077.30%
• Sector: Healthcare
• Industry: Biotechnology

About: Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Employees: 357

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

16,700% more call options, than puts

Call options by funds: $1.34M | Put options by funds: $8K

91% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 66

2.72% more ownership

Funds ownership: 106.15% [Q1] → 108.87% (+2.72%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 36

2% less capital invested

Capital invested by funds: $2.37B [Q1] → $2.33B (-$42.6M) [Q2]

3% less funds holding

Funds holding: 274 [Q1] → 267 (-7) [Q2]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $58 62% upside
• Avg. target: $63 75% upside
• High target: $67 87% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Canaccord Genuity Caitlin Cronin	62% upside $58	Buy Maintained	1 Aug 2025
Stephens & Co. Mason Carrico	87% upside $67	Overweight Reiterated	16 Jun 2025